Authors
Latest:
Evolving With the TimesJill Gilbert, MD, explains how publications must evolve to utilize modern educational platforms to reach readers.
Latest:
Dr Baretti on Entinostat Plus Nivolumab in Advanced PDACMarina Baretti, MD, on results from a phase 2 study of entinostat in combination with nivolumab for the treatment of advanced pancreatic ductal adenocarcinoma.
Latest:
Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRCThorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.
Latest:
Dr Phillips on Ongoing Research in High-Risk MCLTycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.
Latest:
Dr Kim on the Addition of NALIRIFOX to the Pancreatic Cancer Treatment ParadigmDae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.
Latest:
Tumor Lysis Syndrome: Unmet Needs and Future Directions in CareClosing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.
Latest:
Dr Manning-Geist on Secondary Cytoreductive Surgery in Ovarian CancerBeryl Manning-Geist, MD, discusses findings from a study evaluating the effects of primary treatment modality on secondary cytoreduction outcomes in patients with high-grade ovarian cancer.
Latest:
Normalizing Motherhood in MedicineHematology/oncology programs can make it easier and more rewarding for would-be mothers to participate in fellowship.
Latest:
Dr Al-Ali on the Safety and Efficacy of BMS-986158 Plus Ruxolitinib or Fedratinib in MyelofibrosisHaifa Kathrin Al-Ali, MD, discusses the safety and efficacy findings from the dose-escalation portion of the phase 1/2 CA011-023 trial of BMS-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis.
Latest:
Dr Tripathy on the Management of Early-Stage HER2+ Breast CancerDebu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.
Latest:
Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPHSteven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.
Latest:
FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of TherapyDr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.
Latest:
Dr Gillenwater on Phase 1 Data for ASP-1929 Plus Pembrolizumab in HNSCCAnn M. Gillenwater, MD, discusses safety and efficacy data from the phase 1b/2 ASP-1929-181 trial evaluating the antibody-dye conjugate ASP-1929 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Latest:
Dr Reed on Genetic Differences Between Ewing Sarcoma and OsteosarcomaDamon R. Reed, MD, discusses the genetic differences that distinguish Ewing sarcoma from osteosarcoma, as well as unmet needs in patients with these diseases.
Latest:
Yale Cancer Center Experts Present New Research on Obesity, Tobacco, Evolution, and Early Onset Cancers at Leading Oncology ConferenceYale Cancer Center will share data for breakthrough and emerging cancer treatments at the AACR Annual Meeting.
Latest:
Dr. Rintoul on the Importance of MRD Assessment in NSCLCRobert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.
Latest:
Dr Pedersen on the Evolution of Immunotherapy in HCCKatrina S. Pedersen, MD, MS, discusses the evolution of the role of immunotherapy in the treatment of patients with hepatocellular carcinoma.
Latest:
Inside the Clinic: Experts Explore Case Studies in DLBCLMaher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.
Latest:
HIFU Proves Noninferior to Radical Prostatectomy in Localized Prostate CancerHigh-intensity focused ultrasound produced noninferior salvage treatment-free survival vs radical prostatectomy in localized prostate cancer.
Latest:
Dr. Kamath on the Prevalence of FGFR2 Fusions/Rearrangements in CholangiocarcinomaSuneel Kamath, MD, discusses the prevalence of FGFR2 fusions or rearrangements in cholangiocarcinoma.
Latest:
Dr. Sadai on Signs and Symptoms of High-Grade MeningiomasNader Sanai, MD, discusses symptoms associated with high-grade meningiomas, a rare brain tumor.
Latest:
Florida Cancer Specialists & Research Institute Calls for Reform in Value-Based Oncology Care ProgrammingFlorida Cancer Specialists & Research Institute, LLC is calling for reform in value-based oncology care modeling.
Latest:
An Overview of Advanced Basal Cell Carcinoma (BCC) and Currently Available Treatment OptionsDr Hanna defines basal cell carcinoma (BCC), reviews current treatment options and explains the role of cemiplimab for the treatment of advanced BCC.
Latest:
Dr Coopey on Institutional and Societal Initiatives to Support Women in OncologySuzanne B. Coopey, MD, FACS, discusses ways that women in oncology can feel further supported and advocated for in the cancer care space.
Latest:
18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.
Latest:
The Future of Molecular Testing in NSCLCThe panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.
Latest:
Unmet Needs in the Treatment of HR+/HER2- Breast CancerClosing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.
Latest:
Second-Line Treatment of SCLCVamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
